VALENCIA, Spain, April 19,
2024 /PRNewswire/ -- ARTHEx Biotech S.L., a
clinical-stage biotechnology company focused on developing
innovative medicines through the modulation of microRNAs, today
announced an oral presentation at the upcoming Oligonucleotide
& Peptide Therapeutics (TIDES) Conference 2024, being held in a
hybrid format May 14-17, 2024 in
Boston and online.
Details of the oral presentation are as follows:
Presenter: Dr. Frédéric Legros, ARTHEx Biotech
Executive Chairman and CEO
Title: "Use of a Lipophilic-conjugation to Deliver
antimiR-23b into Skeletal Muscle and Nervous System as a Dual
Therapeutic Approach in DM1"
Session: Oligonucleotide Discovery, Preclinical and
Clinical
Date/Time: Friday, May 17,
9:30am
For more information about TIDES, please visit the conference
website here.
About ATX-01
ATX-01 is an antimiR oligonucleotide designed to target microRNA
23b (miR-23b), which is associated
with regulating the expression of MBNL proteins involved in the
pathogenesis of DM1. It has been demonstrated in human DM1
myoblast cell lines that ATX-01 has a unique, dual mechanism of
action which reduces toxic DMPK mRNA and increases MBNL protein
levels. Toxic DMPK and reduced levels of MBNL have been
identified as the molecular underpinnings of DM1. ATX-01 is
being evaluated in the Phase I-IIa ArthemiR™ trial for the
treatment of DM1. ATX-01 has received Orphan Drug Designation
for ATX-01 in DM1 from the US and European authorities.
ATX-01 was discovered through ARTHEx's in-house discovery
engine, which is designed to identify and optimize novel microRNA
modulators and ensure their preferential delivery to target
tissues, for the treatment of diseases in which microRNAs are
involved in the disease pathogenesis.
About Myotonic Dystrophy Type 1
(DM1)
Myotonic dystrophy type 1 (DM1) is a highly disabling disease
affecting more than one million people worldwide. The condition
affects muscles and other tissues (causing respiratory problems,
fatigue, hypersomnia, cardiac abnormalities, severe
gastrointestinal complications, and cognitive and behavioral
impairment). Most commonly, it manifests during adulthood (classic
DM1), although DM1 can develop at birth in a congenital form, or
during childhood. Although signs and symptoms vary among
affected individuals, sadly, with progression of the disease, DM1
patients experience a reduction in the ability to perform
activities of daily living. Moreover, patients have a significantly
shortened lifespan and there is currently no approved treatment to
slow the progression of the disease.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused
on developing innovative medicines through the modulation of
microRNAs. The Company's lead investigational compound,
ATX-01, is being evaluated for the treatment of myotonic dystrophy
type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa
ArthemiR™ trial. ARTHEx is also advancing its in-house
discovery engine to identify and develop microRNA modulators for
other disorders with high unmet medical needs, including
genetically-driven diseases like DM1. The Company
headquarters are in Valencia,
Spain.
For more information, please visit www.arthexbiotech.com
and engage with us on LinkedIn.
Company
Contact.
|
Investor and Media
Contact
|
Frédéric Legros
|
Amy Conrad
|
Executive Chairman and
CEO
|
Juniper
Point
|
flegros@arthexbiotech.com
|
amy@juniper-point.com
|
+33679495790
|
+1
858-366-3243
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-announces-oral-presentation-on-atx-01-at-the-oligonucleotide--peptide-therapeutics-tides-conference-2024-302121361.html
SOURCE ARTHEx Biotech